Form 4 Roivant Sciences Ltd. For: 27 September
Form 4 Roivant Sciences Ltd. For: 27 September…
35,727$
0,64%
Echtzeit-Aktienkurs Roivant Sciences Ltd
Bid:
Ask:
Nachrichten zur Roivant Sciences Ltd Aktie
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants
…
Roivant Sciences: Signifikante Wirksamkeit bei Lungenhochdruck stärkt das Pipeline-Potenzial
Roivant nutzt ein dezentrales Modell zur Marktreife von zugekauften Wirkstoffkandidaten. Mosliciguat senkte in Phase 2 bei PH-ILD-Patienten signifikant den…
Stocks making the biggest moves premarket: Peloton Interactive, Roivant Sciences, Boston Scientific & more
These are the stocks posting the largest moves premarket.…
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
…
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
…
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
…
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
…
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update - Slideshow
…
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript
…
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation - Slideshow
…
Kaufalarm bei Roivant Sciences: Biotech-Beben mit Milliarden-Coup und FDA-Turbo!
Roivant Sciences Ltd. (ROIV) (i.) operiert nach einem ungewöhnlichen und hochgradig agilen Geschäftsmodell in der Biotechnologiebranche. Anstatt als einzelner, starrer Großkonzern aufzutreten,...…
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript
…
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid…
Roivant Sciences receives FDA priority review for dermatomyositis drug
Roivant Sciences receives FDA priority review for dermatomyositis drug…
Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript
…
Roivant Sciences director Gold sells $26.3 million in shares By Investing.com
Roivant Sciences director Gold sells $26.3 million in shares…
Roivant Sciences stock hits all-time high at 16.8 USD By Investing.com
Roivant Sciences stock hits all-time high at 16.8 USD…
Roivant Sciences president Venker sells $25.5m in shares By Investing.com
Roivant Sciences president Venker sells $25.5m in shares…
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice
Does Roivant Sciences Ltd. (ROIV) have what it takes to be a top stock pick for momentum investors? Lets find…
Roivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation Riddle
…
Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript
…
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
…
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a…
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than…
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
…
Roivant Sciences: A Biotech Growth Play With Major Ambitions
…
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
…
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
…
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
…
Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
…
Roivant Sciences Ltd. 2024 Q1 - Results - Earnings Call Presentation
…
Roivant Sciences: Executing On Huge Buyback Program With More To Come
…
Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript
…
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 8% and 10.86%, respectively, for the quarter ended March 2024.…
Moderna: Lizenzgebühren an Arbutus im Fokus - Aktienanalyse
New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Jefferies & Co:
Michael Yee, Analyst von Jefferies & Co, rät in einer aktuellen Aktienanalyse…
Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
…
Roivant Sciences stock target raised to $16 by Goldman Sachs By Investing.com
Roivant Sciences stock target raised to $16 by Goldman Sachs…